| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 12/23/2004 | WO2004111023A1 Thiadiazoline-1-oxide derivative |
| 12/23/2004 | WO2004111020A1 Aniline derivatives |
| 12/23/2004 | WO2004111019A2 Protective groups cleavable by serumal albumins |
| 12/23/2004 | WO2004111012A1 Imidazolidine derivative |
| 12/23/2004 | WO2004111008A2 Use of a compound of formula i for making a pharmaceutical composition |
| 12/23/2004 | WO2004111005A1 Anthranylamide pyridones that inhibit vegfr-2 and vegfr-3 |
| 12/23/2004 | WO2004111002A1 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide |
| 12/23/2004 | WO2004111001A1 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (gcs) |
| 12/23/2004 | WO2004110989A1 N-hydroxy-7-(arylamino)heptanamide derivatives useful for treating hyper-proliferative disorders |
| 12/23/2004 | WO2004110500A1 Radioactively labelled amino acid analogues, their preparation and use |
| 12/23/2004 | WO2004110495A1 Compositions for oral administration of campothecin and its analogs |
| 12/23/2004 | WO2004110490A2 Use of vegf inhibitors for tumor regression |
| 12/23/2004 | WO2004110488A1 Drug for overcoming anticancer agent resistance and method of screening the same |
| 12/23/2004 | WO2004110481A2 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof |
| 12/23/2004 | WO2004110478A1 Inhibitors of cell migration |
| 12/23/2004 | WO2004110477A1 Inhibitors of the leukocyte prommp-9/beta(2) integrin complex |
| 12/23/2004 | WO2004110465A1 An extract of faeces bombycis and the preparation method thereof, as well as an apparatus for diagnosing or treating malignant tumours |
| 12/23/2004 | WO2004110459A1 Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors |
| 12/23/2004 | WO2004110457A1 Matrix metalloproteinases inhibitors for the stimulation and protection of bone marrow stem cells |
| 12/23/2004 | WO2004110455A1 Combination comprising a cdk inhibitor and a topoisomerase i inhibitor for the treatment of cancer and other proliferative diseases |
| 12/23/2004 | WO2004110452A1 2-aminopyrimidine derivatives as raf kinase inhibitors |
| 12/23/2004 | WO2004110439A1 Polyene oxazoles with antitumour activity and processes for their preparation using a streptomyces strain |
| 12/23/2004 | WO2004110438A1 Agent for photodynamic diagnosis and therapy of oncological diseases |
| 12/23/2004 | WO2004110433A1 Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis |
| 12/23/2004 | WO2004110390A2 Anti-cd74 immunoconjugates and methods |
| 12/23/2004 | WO2004094451A3 8$G(B)-VINYL-11$G(B)-($G(V)-SUBSTITUTED)ALKYL-ESTRA-1,3,5(10)-TRIENES |
| 12/23/2004 | WO2004093852A3 Use of steroid derivatives for the treatment of angiotensin ii related disease e.g. cardiovascular and proliferative disorders |
| 12/23/2004 | WO2004087121A3 Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases |
| 12/23/2004 | WO2004085409A3 Compounds and libraries of pyridines, pyrazines, imidazo[1,2-a]pyrazines and 1h-imidazo[4,5-b]pyrazin-2-ones and first and second medical uses thereof |
| 12/23/2004 | WO2004078128A3 Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
| 12/23/2004 | WO2004073375A3 Podophyllotoxin derivatives as antitumor agents |
| 12/23/2004 | WO2004064715A3 Polyhydroxylated pyrrolizidine |
| 12/23/2004 | WO2004054497A3 Use of a trpm8-activating substance for the treatment of tumours |
| 12/23/2004 | WO2004049095A3 Betaine and salicylic acid compositions |
| 12/23/2004 | WO2004045563A3 Method of treatment of myocardial infarction |
| 12/23/2004 | WO2003106692A3 Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| 12/23/2004 | WO2003101995A8 Camptothecins with a modified lactone ring |
| 12/23/2004 | WO2003050236A3 Human genes and gene expression products isolated from human prostate |
| 12/23/2004 | US20040260069 Modified anti-tnf aplha antibody |
| 12/23/2004 | US20040259959 Administering drug to reduce activity to cells with lycopene to remove melanomas |
| 12/23/2004 | US20040259957 Compounds for treatment of cancer, prodrugs |
| 12/23/2004 | US20040259945 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 12/23/2004 | US20040259936 Patients in need of anticancer treatment or treatment of lymphomas or autoimmune disease |
| 12/23/2004 | US20040259930 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 12/23/2004 | US20040259929 Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
| 12/23/2004 | US20040259928 Enzyme inhibitors for antidiabetic agents, antitumor disorders, treatment of skin disorters, anticancer agents and cognitive activators for Alzheimers disease treatment |
| 12/23/2004 | US20040259926 carbocyclic sulfides such as {4-[5-Methoxy-6-methyl-2-(2H-tetrazol-5-ylcarbamoyl)-benzo[b]thiophene-3-yloxy]-phenyl}-acetic acid ethyl ester, used as phosphatidyl inositol 3-kinase inhibitors; antiinflammatory and anticarcinogenic agents; prophylaxis of cardiovascular disorders |
| 12/23/2004 | US20040259922 Epothilone derivatives, a process for their production thereof and their use |
| 12/23/2004 | US20040259894 inhibitors of cyclin-dependent kinases (CDKs); cancer, leukemia, psoriasis |
| 12/23/2004 | US20040259879 Antiarthritic agents; colon cancer, neurodegenerative agents |
| 12/23/2004 | US20040259869 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 12/23/2004 | US20040259864 Substituted pyrimidinone derivatives as ligands of integrin receptors |
| 12/23/2004 | US20040259863 Type 4 phosphodiesterase inhibitors and uses thereof |
| 12/23/2004 | US20040259840 Using phosphoglycerides, lipid having sphingosine base, glycerides and sterol; wound healing agents; atherosclerosis |
| 12/23/2004 | US20040259834 Therapeutic composition containing at least diflomotecan and capecitabine |
| 12/23/2004 | US20040259829 Carboxylesterase; antitumor agents; drug screening; bioassay |
| 12/23/2004 | US20040259826 Mitotic kinesin inhibitors |
| 12/23/2004 | US20040259821 In nonaqueous solvent; therapy for blood disorders; anticancer agents |
| 12/23/2004 | US20040259820 Kit for delivering decitabine in vivo |
| 12/23/2004 | US20040259815 Synergistic mixture containing tyrosine kinase inhibitor with carotenoils, flavonoids, apigenin |
| 12/23/2004 | US20040259810 Porphyrin derivatives for photodynamic therapy |
| 12/23/2004 | US20040259800 Apoptosis of rectum and prostate cancer |
| 12/23/2004 | US20040259798 Drugs; integrin antagonist; antiinflammatory agents; leukemia therapy |
| 12/23/2004 | US20040259781 Drug screening ; polypeptide interfers with binding of fibronectin to; anticancer agents; antihistamines, antiarthritic agents, autoimmune disease, wound healing agents |
| 12/23/2004 | US20040259779 Novel neurotrophic factors |
| 12/23/2004 | US20040259767 Antiproliferative agents; therapy for human progessive leukoencephalophy ; suppression of dna viruses; anticancer agents |
| 12/23/2004 | US20040259248 RNA interference mediating small RNA molecules |
| 12/23/2004 | US20040259247 short interfering RNAs for use treating diseases, in protein separation or purification, in drug screening; cell with target gene-specific knockout phenotype; double stranded RNA; RNA fragments are the sequence-specific mediators of RNAi (RNA interference) |
| 12/23/2004 | US20040259202 Novel angiogenesis inhibitor |
| 12/23/2004 | US20040259201 Recombinant surfactant protein D compositions and methods of use thereof |
| 12/23/2004 | US20040259196 T cell receptor variants expressed in mesenchymal cells and uses thereof |
| 12/23/2004 | US20040259192 into two fragments, using the human matrix metalloproteinase MMP-3; administering 3-(3-mercaptopropyl)-1-methyl-(1H,3H)quinazoline-2,4-dione and/or 3-(2'-mercaptoethylamino)-2H-1,2,4-benzothiadiazine-1,1-dioxide to treat tumors or diabetic retinopathy; also wound healing, cardiac infarction treatment |
| 12/23/2004 | US20040259174 designated SM047, as diagnostic aid; test kits; hybridomas that make said antibody |
| 12/23/2004 | US20040259156 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 12/23/2004 | US20040259150 Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| 12/23/2004 | US20040259126 MN gene and protein |
| 12/23/2004 | US20040259110 Gene PRV-1 and its use |
| 12/23/2004 | US20040259103 NKR (Natural Killer Receptor); rapidly analyze physiological and pathological situations linked to these repertoires; use in diagnosise/prognosis of patients for transplant acceptance, resistance to infections and disease, and in drug screening for autoimmune diseases, antitumor agents, and antibiotics |
| 12/23/2004 | US20040259097 Method for the in vitro synthesis of short double stranded rnas |
| 12/23/2004 | US20040259084 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 12/23/2004 | US20040258813 Dehydrating; steaming; drying; freezing; pulverization |
| 12/23/2004 | US20040258782 Isolation of lutein from alfalfa |
| 12/23/2004 | US20040258772 Methods of treating angiogenesis, tumor growth, and metastasis |
| 12/23/2004 | US20040258771 Reduced toxicity cisplatin formulations and methods for using the same |
| 12/23/2004 | US20040258770 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, a platinum compound, an antineoplastic antimetabolic agent and folinic acid; colorectal cancer |
| 12/23/2004 | US20040258755 Dissolved cis[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(alkanoyloxy)]platinum(II) in 2-methyl-2-propanol; stabile, easily handled injection; fine, homogenous suspension; controlled particle size distribution |
| 12/23/2004 | US20040258754 Compositions for oral administration of camptothecin and its analogs |
| 12/23/2004 | US20040258730 Sustained relase film comprises (11Apha ,13E,15 alpha )-9-oxo-11,15-dihydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranor-5-thiaprost-13-enoic acid methyl ester to treat bone mass disorders; osteoporosis, metastatic bone, hypercalcemia, and Paget's disease |
| 12/23/2004 | US20040258696 Compositions and methods for the diagnosis and treatment of tumor |
| 12/23/2004 | US20040258693 Customization of cancer therapy by adminstering modifying antibodies from antigens expressed from cancerous tissue which are cytotoxic to cancer cells while non-toxic to non-cancerous cells; monoclonal antibody antigen binding fragment having identifying characteristics to deposit PTA-4890 at the ATCC |
| 12/23/2004 | US20040258692 Method for the treatment of cardiotoxicity induced by antitumor compounds |
| 12/23/2004 | US20040258691 Treating psoriasis in a patient by administering a therapeutically effective amount of an antibody immunospecific for vetronectin receptor av beta 3; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3; cell adhesion |
| 12/23/2004 | US20040258689 Augmenting activin induced signaling in cells; screening for complex inhibitors; treatment of reproductive, developmental, skin, bone, hepatic, hematopoietic and/or central nervous system disorders; prostrate cancer |
| 12/23/2004 | US20040258682 Monoclonal antibody or fragment engineered in non-Fc constant heavy or light region; immunoconjugates for cancer diagnosis and therapy |
| 12/23/2004 | US20040258675 Novel mutated form of arginine deiminase |
| 12/23/2004 | US20040258663 Maintaining sustained levels and optimizing intranasal dosing schedules without causing intolerable side effects |
| 12/23/2004 | US20040258662 Antineoplastic agents |
| 12/23/2004 | US20040258657 Antitumor agent containing cyclic polylactic acid |
| 12/23/2004 | US20040258656 Identified via SELEX method; phosphate-containing ligand is conjugated to polyoxyethylene glycol; transforming growth factor (TGF); pharmacokinetics |
| 12/23/2004 | US20040258620 In vivo stability, biocompatibility, organ specificity; low dosage, rapid excretion; nuclear magnetic resonance diagnostic imaging, radiotherapy |